A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)
Laufzeit: 01.01.2022 - 31.12.2026
imported
Kurzfassung
Compare efficacy of durvalumab + tremelimumab + EV relative to cystectomy on pCR rate and EFS Compare the efficacy of durvalumab + EV relative to cystectomy on pCR rate, EFS, OS, EFS24, OS5, DFS, pDS rate, DSS, and metastasis-free survival (MFS) Compare the efficacy of durvalumab + tremelimumab + EV relative to cystectomy on OS, EFS24, OS5, DFS, pDS rate, DSS, and MFS
Beteiligte Einrichtungen
